BACKGROUND: Avoiding donor-specific antibody (DSA) is difficult for sensitized patients. Improved understanding of the risk of low level DSA is needed. METHODS: We retrospectively compared the outcomes of 954 patients transplanted with varied levels of baseline DSA detected by single antigen beads and B flow cytometric crossmatch (XM). Patients were grouped as follows: -DSA/-XM, +DSA/-XM, +DSA/low +XM, +DSA/high +XM, and -DSA/+XM and followed up for a mean of 4.1 ± 1.9 years (similar among groups, P = 0.49). RESULTS: Death-censored allograft survival was similar in all groups except the +DSA/high +XM group, which was lower at 79.1% versus 96.2% in the -DSA/-XM group (P < 0.01). The incidence of chronic antibody-mediated rejection (CAMR) based on surveillance biopsy was higher with increasing DSA (8.2% -DSA/-XM, 17.0% +DSA/-XM, 30.6% +DSA/low +XM, and 51.2% +DSA/high +XM, P < 0.01), but similar in groups without baseline DSA (8.1% -DSA/-XM vs 15.4% -DSA/+XM, P = 0.19). Having a calculated panel-reactive antibody (cPRA) of 80% or greater was independently associated with CAMR (hazard ratio, 5.2; P = 0.03) even when DSA was undetected at baseline. By 2 years posttransplant, the incidence of CAMR was 19.4% in patients with cPRA of 80% or greater and undetected DSA and negative XM at baseline. CONCLUSIONS: Kidney transplantation with low-level DSA with or without a low positive XM is a reasonable option for highly sensitized patients and may be advantageous compared with waiting for a negative XM deceased donor. The risk for CAMR is low in patients with no DSA even if the XM is positive. Patients with cPRA of 80% or greater are at risk for CAMR even if no DSA is detected.
BACKGROUND: Avoiding donor-specific antibody (DSA) is difficult for sensitized patients. Improved understanding of the risk of low level DSA is needed. METHODS: We retrospectively compared the outcomes of 954 patients transplanted with varied levels of baseline DSA detected by single antigen beads and B flow cytometric crossmatch (XM). Patients were grouped as follows: -DSA/-XM, +DSA/-XM, +DSA/low +XM, +DSA/high +XM, and -DSA/+XM and followed up for a mean of 4.1 ± 1.9 years (similar among groups, P = 0.49). RESULTS: Death-censored allograft survival was similar in all groups except the +DSA/high +XM group, which was lower at 79.1% versus 96.2% in the -DSA/-XM group (P < 0.01). The incidence of chronic antibody-mediated rejection (CAMR) based on surveillance biopsy was higher with increasing DSA (8.2% -DSA/-XM, 17.0% +DSA/-XM, 30.6% +DSA/low +XM, and 51.2% +DSA/high +XM, P < 0.01), but similar in groups without baseline DSA (8.1% -DSA/-XM vs 15.4% -DSA/+XM, P = 0.19). Having a calculated panel-reactive antibody (cPRA) of 80% or greater was independently associated with CAMR (hazard ratio, 5.2; P = 0.03) even when DSA was undetected at baseline. By 2 years posttransplant, the incidence of CAMR was 19.4% in patients with cPRA of 80% or greater and undetected DSA and negative XM at baseline. CONCLUSIONS: Kidney transplantation with low-level DSA with or without a low positive XM is a reasonable option for highly sensitized patients and may be advantageous compared with waiting for a negative XM deceased donor. The risk for CAMR is low in patients with no DSA even if the XM is positive. Patients with cPRA of 80% or greater are at risk for CAMR even if no DSA is detected.
Authors: A R Tambur; N D Herrera; K M K Haarberg; M F Cusick; R A Gordon; J R Leventhal; J J Friedewald; D Glotz Journal: Am J Transplant Date: 2015-04-30 Impact factor: 8.086
Authors: S Hariharan; M B Adams; D C Brennan; C L Davis; M R First; C P Johnson; R Ouseph; V R Peddi; C J Pelz; A M Roza; F Vincenti; V George Journal: Transplantation Date: 1999-09-15 Impact factor: 4.939
Authors: G Einecke; B Sis; J Reeve; M Mengel; P M Campbell; L G Hidalgo; B Kaplan; P F Halloran Journal: Am J Transplant Date: 2009-11 Impact factor: 8.086
Authors: Ashley A Vo; Marina Lukovsky; Mieko Toyoda; Jennifer Wang; Nancy L Reinsmoen; Chih-Hung Lai; Alice Peng; Rafael Villicana; Stanley C Jordan Journal: N Engl J Med Date: 2008-07-17 Impact factor: 91.245
Authors: C Lefaucheur; C Suberbielle-Boissel; G S Hill; D Nochy; J Andrade; C Antoine; C Gautreau; D Charron; D Glotz Journal: Contrib Nephrol Date: 2008-10-31 Impact factor: 1.580
Authors: M Haas; B Sis; L C Racusen; K Solez; D Glotz; R B Colvin; M C R Castro; D S R David; E David-Neto; S M Bagnasco; L C Cendales; L D Cornell; A J Demetris; C B Drachenberg; C F Farver; A B Farris; I W Gibson; E Kraus; H Liapis; A Loupy; V Nickeleit; P Randhawa; E R Rodriguez; D Rush; R N Smith; C D Tan; W D Wallace; M Mengel Journal: Am J Transplant Date: 2014-02 Impact factor: 8.086
Authors: Ek Khoon Tan; Andrew Bentall; Patrick G Dean; Mohammed F Shaheen; Mark D Stegall; Carrie A Schinstock Journal: Transplantation Date: 2019-11 Impact factor: 4.939
Authors: Robin Schmitz; Zachary W Fitch; Paul M Schroder; Ashley Y Choi; Annette M Jackson; Stuart J Knechtle; Jean Kwun Journal: Transpl Int Date: 2020-01 Impact factor: 3.782
Authors: Carrie A Schinstock; Andrew J Bentall; Byron H Smith; Lynn D Cornell; Matthew Everly; Manish J Gandhi; Mark D Stegall Journal: Am J Transplant Date: 2018-12-15 Impact factor: 8.086
Authors: Ronald F Parsons; Arslan Zahid; Shalini Bumb; Hannah Decker; Harold C Sullivan; Frances Eun-Hyung Lee; Idelberto Raul Badell; Mandy L Ford; Christian P Larsen; Thomas C Pearson; Annette M Jackson; Dong-Feng Chen; Matthew Levine; Malek Kamoun; Robert A Bray; Howard M Gebel Journal: Am J Transplant Date: 2019-10-08 Impact factor: 8.086
Authors: Carrie A Schinstock; Darshana M Dadhania; Matthew J Everly; Byron Smith; Manish Gandhi; Evan Farkash; Vijay K Sharma; Milagros Samaniego-Picota; Mark D Stegall Journal: Transpl Int Date: 2019-02-08 Impact factor: 3.782
Authors: Malte Ziemann; Wolfgang Altermann; Katharina Angert; Wolfgang Arns; Anette Bachmann; Tamam Bakchoul; Bernhard Banas; Annette von Borstel; Klemens Budde; Vanessa Ditt; Gunilla Einecke; Ute Eisenberger; Thorsten Feldkamp; Siegfried Görg; Martina Guthoff; Antje Habicht; Michael Hallensleben; Falko M Heinemann; Nicole Hessler; Christian Hugo; Matthias Kaufmann; Teresa Kauke; Martina Koch; Inke R König; Christine Kurschat; Claudia Lehmann; Matthias Marget; Anja Mühlfeld; Martin Nitschke; Luiza Pego da Silva; Carmen Quick; Axel Rahmel; Thomas Rath; Petra Reinke; Lutz Renders; Florian Sommer; Bernd Spriewald; Oliver Staeck; Dirk Stippel; Caner Süsal; Bernhard Thiele; Daniel Zecher; Nils Lachmann Journal: Clin J Am Soc Nephrol Date: 2019-06-18 Impact factor: 10.614